Index S&P 500 P/E 22.41 EPS (ttm) 6.29 Insider Own 0.32% Shs Outstand 87.50M Perf Week -0.07%
Market Cap 12.29B Forward P/E 18.27 EPS next Y 7.72 Insider Trans 1.38% Shs Float 86.85M Perf Month 4.88%
Income 554.10M PEG 3.86 EPS next Q 1.98 Inst Own 104.38% Short Float 3.13% Perf Quarter 21.38%
Sales 3.67B P/S 3.34 EPS this Y 3.86% Inst Trans 1.72% Short Ratio 3.84 Perf Half Y 4.28%
Book/sh 16.36 P/B 8.62 EPS next Y 6.84% ROA 12.39% Short Interest 2.72M Perf Year 35.33%
Cash/sh 8.58 P/C 16.44 EPS next 5Y 5.80% ROE 43.22% 52W Range 95.94 - 146.41 Perf YTD 11.36%
Dividend Est. 1.91 (1.35%) P/FCF 24.71 EPS past 5Y 5.98% ROI 15.69% 52W High -3.64% Beta 1.12
Dividend TTM 1.86 (1.32%) Quick Ratio 1.23 Sales past 5Y 6.18% Gross Margin 43.79% 52W Low 47.05% ATR (14) 2.86
Dividend Ex-Date Sep 20, 2024 Current Ratio 1.66 EPS Y/Y TTM 7.85% Oper. Margin 20.58% RSI (14) 61.42 Volatility 2.10% 1.92%
Employees 12400 Debt/Eq 1.79 Sales Y/Y TTM 1.78% Profit Margin 15.08% Recom 2.69 Target Price 135.22
Option/Short Yes / Yes LT Debt/Eq 1.48 EPS Q/Q 10.19% Payout 29.41% Rel Volume 0.62 Prev Close 143.75
Sales Surprise 1.26% EPS Surprise 5.50% Sales Q/Q 5.82% Earnings Jul 24 BMO Avg Volume 707.60K Price 141.08
SMA20 2.02% SMA50 5.94% SMA200 11.72% Trades
Volume 378,842 Change -1.86%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-04-24 Downgrade Barclays
Equal Weight → Underweight
$122 → $116
Feb-23-24 Downgrade Mizuho
Buy → Neutral
$140 → $141
Feb-21-24 Downgrade Wells Fargo
Overweight → Equal Weight
$139 → $140
Dec-04-23 Downgrade Barclays
Overweight → Equal Weight
$130 → $119
Oct-19-23 Downgrade Vertical Research
Buy → Hold
$128 → $100
Sep-06-23 Downgrade Longbow
Buy → Neutral
Jan-03-23 Upgrade Vertical Research
Hold → Buy
$128
Jul-11-22 Downgrade BofA Securities
Neutral → Underperform
$110
Feb-16-22 Reiterated Wells Fargo
Overweight
$157 → $147
Feb-16-22 Reiterated Morgan Stanley
Equal-Weight
$146 → $134
Feb-16-22 Reiterated Mizuho
Buy
$170 → $145
Feb-16-22 Reiterated Credit Suisse
Neutral
$142 → $134
Dec-17-21 Initiated Mizuho
Buy
$170
Dec-08-21 Downgrade BofA Securities
Buy → Neutral
$163 → $142
Nov-29-21 Initiated Atlantic Equities
Overweight
$155
Oct-08-21 Initiated Wells Fargo
Overweight
$159
Sep-10-21 Upgrade Goldman
Neutral → Buy
$158 → $174
Apr-06-21 Upgrade Barclays
Underweight → Overweight
$107 → $150
Mar-16-21 Upgrade Longbow
Neutral → Buy
Nov-11-20 Upgrade BofA Securities
Neutral → Buy
$128
Show Previous Ratings
Sep-18-24 09:15AM
Sep-17-24 02:00PM
Sep-16-24 08:00AM
Sep-13-24 06:31PM
Sep-12-24 09:45AM
09:40AM
Loading…
09:40AM
Sep-09-24 03:42AM
Sep-05-24 05:10PM
Aug-27-24 09:40AM
Aug-23-24 11:30AM
Aug-19-24 09:55AM
Aug-14-24 12:36PM
Aug-08-24 09:00AM
Aug-06-24 08:36AM
Aug-05-24 03:07AM
05:00PM
Loading…
Jul-31-24 05:00PM
Jul-30-24 07:01PM
07:00PM
09:40AM
Jul-29-24 09:15AM
03:03AM
Jul-26-24 02:43PM
(Investor's Business Daily)
Jul-25-24 01:03AM
Jul-24-24 03:45PM
11:40AM
07:05AM
06:08AM
05:41AM
05:35AM
(Associated Press Finance)
05:30AM
03:07AM
Loading…
Jul-23-24 03:07AM
Jul-19-24 10:56AM
03:43AM
Jul-17-24 10:01AM
Jul-15-24 04:24AM
Jul-09-24 05:30PM
12:10PM
Jul-01-24 08:00AM
Jun-28-24 12:16PM
07:30AM
Jun-25-24 09:00AM
Jun-23-24 06:33PM
Jun-21-24 03:52PM
Jun-20-24 02:04PM
Jun-19-24 08:00AM
Jun-18-24 09:00AM
Jun-12-24 10:57AM
Jun-11-24 07:30AM
Jun-05-24 12:12PM
Jun-04-24 07:00AM
May-30-24 11:33AM
May-29-24 09:30AM
May-28-24 01:00PM
May-22-24 05:00PM
May-21-24 07:45PM
May-20-24 04:51PM
04:15PM
May-15-24 09:30AM
May-14-24 12:00PM
May-08-24 04:30PM
Apr-30-24 11:50AM
Apr-26-24 05:12PM
01:26PM
11:32AM
09:25AM
07:33AM
01:05AM
Apr-25-24 11:21AM
09:59AM
09:52AM
07:42AM
07:34AM
07:05AM
06:03AM
05:40AM
(Associated Press Finance)
05:30AM
Apr-23-24 10:03AM
Apr-18-24 10:01AM
Apr-12-24 10:57AM
Apr-11-24 05:00PM
06:45AM
Apr-09-24 09:00AM
Apr-05-24 12:10PM
08:00AM
Apr-04-24 05:00PM
Apr-03-24 09:00AM
Apr-02-24 09:00AM
Mar-26-24 01:30PM
10:14AM
Mar-21-24 11:30AM
Mar-12-24 09:02AM
08:08AM
Mar-07-24 10:08AM
Mar-06-24 05:00PM
Mar-05-24 04:30PM
12:58PM
09:00AM
Mar-04-24 07:00AM
Feb-26-24 09:03AM
Feb-21-24 08:47AM
Allegion Plc engages in the provision of security products and solutions that keep people safe, secure, and productive. It operates through the Allegion Americas and Allegion International segments. The Allegion Americas segment offers security products, services, and solutions throughout North America. The Allegion International segment refers to security products, services, and solutions primarily throughout Europe, Asia and Oceania. The company was founded on May 9, 2013 and is headquartered in Dublin, Ireland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Jeffrey Braun Senior Vice President Advisory Aug 05 '24 Proposed Sale 126.87 7,675 973,737 Aug 05 05:58 PM Stone John H President and CEO Jul 26 '24 Buy 134.99 5,000 674,925 118,640 Jul 30 04:23 PM MIZELL STEVEN Director Jul 26 '24 Buy 136.53 1,000 136,530 5,545 Jul 30 04:20 PM Kemp Tracy L SVP-Chief Info. & Digital Ofr. May 28 '24 Sale 121.98 2,194 267,629 11,103 May 30 04:34 PM Eckersley Timothy P Sr. VP-Allegion International Mar 11 '24 Option Exercise 71.83 5,047 362,551 40,614 Mar 12 07:59 PM Eckersley Timothy P Sr. VP-Allegion International Mar 11 '24 Sale 130.63 5,089 664,799 0 Mar 12 07:59 PM Eckersley Timothy P Sr. VP-Allegion International Mar 11 '24 Sale 129.99 5,047 656,060 35,567 Mar 12 07:59 PM Eckersley Timothy P Sr. VP-Allegion International Mar 12 '24 Sale 132.75 2,291 304,130 33,276 Mar 12 07:59 PM Stone John H President and CEO Feb 22 '24 Buy 132.41 10,000 1,324,146 104,248 Feb 26 08:23 PM Martens Robert C. SVP Chief Innovation & Design Feb 22 '24 Option Exercise 106.64 5,391 574,893 12,946 Feb 26 08:16 PM Martens Robert C. SVP Chief Innovation & Design Feb 22 '24 Sale 132.84 5,391 716,162 7,555 Feb 26 08:16 PM Braun Jeffrey N SVP and GC Feb 21 '24 Sale 131.00 3,000 393,000 9,653 Feb 22 04:18 PM Eckersley Timothy P Sr. VP-Allegion International Dec 15 '23 Sale 118.00 6,103 720,159 36,166 Dec 19 04:17 PM Martens Robert C. SVP Chief Innovation & Design Dec 08 '23 Sale 110.52 4,068 449,605 6,714 Dec 12 05:12 PM
Index DJIA, S&P 500 P/E 21.64 EPS (ttm) 5.40 Insider Own 0.11% Shs Outstand 2.53B Perf Week 0.80%
Market Cap 296.05B Forward P/E 12.00 EPS next Y 9.74 Insider Trans 0.00% Shs Float 2.53B Perf Month 0.66%
Income 13.74B PEG - EPS next Q 1.74 Inst Own 78.79% Short Float 1.02% Perf Quarter -10.65%
Sales 62.19B P/S 4.76 EPS this Y 431.22% Inst Trans 0.64% Short Ratio 2.63 Perf Half Y -5.52%
Book/sh 17.19 P/B 6.80 EPS next Y 21.37% ROA 12.65% Short Interest 25.91M Perf Year 8.84%
Cash/sh 4.50 P/C 25.98 EPS next 5Y - ROE 33.39% 52W Range 99.14 - 134.63 Perf YTD 7.13%
Dividend Est. 3.14 (2.69%) P/FCF 22.52 EPS past 5Y -42.70% ROI 17.54% 52W High -13.25% Beta 0.40
Dividend TTM 3.08 (2.64%) Quick Ratio 1.22 Sales past 5Y 7.72% Gross Margin 72.33% 52W Low 17.81% ATR (14) 2.21
Dividend Ex-Date Sep 16, 2024 Current Ratio 1.47 EPS Y/Y TTM 340.50% Oper. Margin 26.04% RSI (14) 48.92 Volatility 1.75% 1.82%
Employees 72000 Debt/Eq 0.87 Sales Y/Y TTM 8.43% Profit Margin 22.09% Recom 1.42 Target Price 140.05
Option/Short Yes / Yes LT Debt/Eq 0.80 EPS Q/Q 191.12% Payout 2065.60% Rel Volume 0.75 Prev Close 117.23
Sales Surprise 1.53% EPS Surprise 5.17% Sales Q/Q 7.25% Earnings Jul 30 BMO Avg Volume 9.87M Price 116.79
SMA20 -0.04% SMA50 -1.25% SMA200 -4.47% Trades
Volume 6,390,932 Change -0.37%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-11-24 Downgrade Societe Generale
Hold → Sell
$104
Jan-04-24 Upgrade TD Cowen
Market Perform → Outperform
$125 → $135
Nov-09-23 Initiated Deutsche Bank
Buy
$115
Oct-27-23 Upgrade BMO Capital Markets
Market Perform → Outperform
$132
Oct-20-23 Upgrade UBS
Neutral → Buy
$117 → $122
Jul-14-23 Initiated HSBC Securities
Hold
$123
Apr-13-23 Upgrade Citigroup
Neutral → Buy
$105 → $130
Mar-28-23 Downgrade Societe Generale
Buy → Hold
Mar-13-23 Downgrade Wells Fargo
Overweight → Equal Weight
$120 → $115
Mar-06-23 Initiated Jefferies
Buy
$125
Feb-22-23 Upgrade Wolfe Research
Peer Perform → Outperform
$127
Jan-04-23 Upgrade BofA Securities
Neutral → Buy
$110 → $130
Nov-18-22 Initiated Credit Suisse
Outperform
$120
Oct-10-22 Upgrade Guggenheim
Neutral → Buy
Sep-14-22 Upgrade Berenberg
Hold → Buy
$95 → $100
Jul-06-22 Upgrade Daiwa Securities
Neutral → Buy
$89 → $102
Jun-06-22 Resumed SVB Leerink
Outperform
$102
Apr-06-22 Resumed Morgan Stanley
Equal-Weight
$80
Dec-17-21 Initiated Goldman
Buy
$93
Dec-16-21 Initiated Daiwa Securities
Neutral
$70
Show Previous Ratings
Today 10:48AM
09:00AM
07:30AM
Sep-19-24 09:00AM
Sep-18-24 02:45PM
06:45AM
Loading…
06:45AM
04:52AM
Sep-17-24 07:58AM
07:51AM
06:00AM
Sep-16-24 07:00AM
Sep-15-24 10:30AM
08:45AM
Sep-14-24 12:40PM
10:47AM
10:35AM
Loading…
10:35AM
10:30AM
08:10AM
03:15AM
Sep-12-24 03:10PM
(The Wall Street Journal)
07:00AM
12:25AM
Sep-11-24 06:45AM
06:30AM
Sep-09-24 01:55PM
(The Wall Street Journal)
09:59AM
08:02AM
Sep-07-24 11:30AM
Sep-06-24 06:14PM
12:10PM
07:00AM
Loading…
Sep-05-24 07:00AM
04:32AM
Sep-04-24 03:00PM
06:45AM
06:40AM
04:12AM
(Pharmaceutical Technology)
Sep-03-24 11:32PM
01:22PM
(The Wall Street Journal)
09:40AM
08:10AM
06:45AM
Aug-29-24 10:35AM
09:33AM
07:30AM
06:45AM
06:30AM
Aug-28-24 04:52AM
Aug-27-24 08:52AM
07:35AM
06:45AM
05:32AM
Aug-26-24 03:22PM
(Pharmaceutical Technology)
12:00PM
06:45AM
Aug-23-24 02:10PM
09:00AM
Aug-22-24 07:00AM
Aug-21-24 09:29AM
Aug-19-24 08:04AM
Aug-17-24 03:21PM
Aug-16-24 08:54PM
06:09PM
Aug-15-24 05:30PM
12:34PM
10:49AM
07:49AM
Aug-14-24 06:15AM
Aug-09-24 03:33PM
(Pharmaceutical Technology)
03:18PM
08:09AM
(The Wall Street Journal)
06:45AM
06:32AM
05:59AM
Aug-08-24 12:23PM
09:00AM
06:45AM
Aug-07-24 07:57AM
Aug-06-24 09:00AM
06:45AM
Aug-02-24 06:00PM
02:22PM
Aug-01-24 08:00AM
Jul-31-24 09:53AM
(Pharmaceutical Technology)
07:33AM
03:20AM
(The Wall Street Journal)
01:58AM
(Thomson Reuters StreetEvents)
Jul-30-24 02:15PM
01:30PM
12:09PM
12:05PM
12:00PM
11:40AM
11:25AM
10:54AM
(Investor's Business Daily)
10:36AM
(The Wall Street Journal)
10:35AM
10:09AM
08:45AM
07:17AM
06:45AM
(Associated Press Finance)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Guindo Chirfi Chief Marketing Officer Aug 05 '24 Option Exercise 115.20 36,901 4,250,995 57,782 Aug 06 12:20 PM Smart Dalton SVP Fin. - Global Controller May 03 '24 Option Exercise 128.26 2,046 262,420 4,708 May 06 04:10 PM Smart Dalton SVP Fin. - Global Controller May 04 '24 Option Exercise 127.51 612 78,036 4,730 May 06 04:10 PM DeLuca Richard R. EVP&Pres, Merck Animal Heallth May 04 '24 Option Exercise 127.51 27,126 3,458,836 163,720 May 06 04:08 PM Klobuchar Michael A EVP - Chief Strategy Officer May 04 '24 Option Exercise 127.51 887 113,101 24,058 May 06 04:06 PM Oosthuizen Johannes Jacobus President, U.S. Market May 04 '24 Option Exercise 127.51 912 116,289 24,271 May 06 04:01 PM Romanelli Joseph President, Human Health Int?l May 02 '24 Option Exercise 128.80 2,262 291,346 21,831 May 02 04:29 PM Smart Dalton SVP Fin. - Global Controller May 02 '24 Option Exercise 128.80 381 49,073 3,048 May 02 04:23 PM Merck & Co., Inc. 10% Owner Mar 11 '24 Buy 23.00 21,397,205 492,135,715 1,000 Mar 11 03:27 PM Litchfield Caroline EVP & CFO Feb 14 '24 Option Exercise 58.08 38,291 2,223,941 89,199 Feb 15 04:03 PM Litchfield Caroline EVP & CFO Feb 14 '24 Sale 125.50 38,291 4,805,520 50,908 Feb 15 04:03 PM Davis Robert M Chairman, CEO & President Feb 13 '24 Option Exercise 74.18 150,000 11,127,160 498,327 Feb 15 04:01 PM Davis Robert M Chairman, CEO & President Feb 14 '24 Option Exercise 73.73 85,021 6,268,598 433,348 Feb 15 04:01 PM Davis Robert M Chairman, CEO & President Feb 13 '24 Sale 125.85 150,000 18,877,424 348,327 Feb 15 04:01 PM Davis Robert M Chairman, CEO & President Feb 14 '24 Sale 125.40 85,021 10,661,574 348,327 Feb 15 04:01 PM Romanelli Joseph President, Human Health Int?l Feb 13 '24 Sale 124.89 1,000 124,888 19,569 Feb 14 04:03 PM Li Dean Y Executive VP & President, MRL Feb 09 '24 Option Exercise 62.07 14,702 912,553 60,944 Feb 12 04:03 PM Li Dean Y Executive VP & President, MRL Feb 09 '24 Sale 125.50 14,702 1,845,083 46,242 Feb 12 04:03 PM Williams David Michael EVP,Chief Info&Digital Officer Feb 07 '24 Sale 127.57 1,451 185,108 19,812 Feb 08 04:04 PM Oosthuizen Johannes Jacobus President, U.S. Market Feb 02 '24 Option Exercise 78.80 20,937 1,649,906 42,286 Feb 05 04:01 PM Oosthuizen Johannes Jacobus President, U.S. Market Feb 02 '24 Sale 127.17 18,959 2,411,111 23,327 Feb 05 04:01 PM MIZELL STEVEN EVP, Chief HR Officer Feb 02 '24 Option Exercise 73.65 32,994 2,430,159 74,313 Feb 02 04:07 PM MIZELL STEVEN EVP, Chief HR Officer Feb 02 '24 Sale 126.65 50,694 6,420,349 23,619 Feb 02 04:07 PM Zachary Jennifer EVP, General Counsel Feb 02 '24 Option Exercise 87.10 19,417 1,691,221 78,557 Feb 02 04:05 PM Zachary Jennifer EVP, General Counsel Feb 02 '24 Sale 126.97 49,499 6,284,779 29,058 Feb 02 04:05 PM Oosthuizen Johannes Jacobus President, U.S. Market Nov 09 '23 Sale 102.38 2,081 213,061 18,191 Nov 13 07:36 AM DeLuca Richard R. EVP&Pres, Merck Animal Heallth Nov 08 '23 Sale 105.03 43,823 4,602,668 111,764 Nov 09 09:04 AM Oosthuizen Johannes Jacobus President, U.S. Market Oct 30 '23 Option Exercise 102.82 915 94,080 20,723 Oct 31 11:08 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
